2012
DOI: 10.1253/circj.cj-12-0498
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Periprocedural Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
66
1
3

Year Published

2012
2012
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 79 publications
(73 citation statements)
references
References 27 publications
3
66
1
3
Order By: Relevance
“…Thus, their study was not one that demonstrates the superiority of dabigatran over warfarin. 4 In contrast, important results from a multicenter prospective registry comparing the feasibility and safety of dabigatran with uninterrupted warfarin have been reported by Lakkireddy et al 5 In their analysis comparing 145 patients on uninterrupted warfarin with 145 patients taking dabigatran, the latter group had a significantly higher rate of major bleeding complications (9 patients, 6%), all of which were pericardial tamponade requiring drainage. Major bleeding (pericardial tamponade) was observed in only one patient (1%) in the warfarin group.…”
Section: Article P 2337mentioning
confidence: 95%
“…Thus, their study was not one that demonstrates the superiority of dabigatran over warfarin. 4 In contrast, important results from a multicenter prospective registry comparing the feasibility and safety of dabigatran with uninterrupted warfarin have been reported by Lakkireddy et al 5 In their analysis comparing 145 patients on uninterrupted warfarin with 145 patients taking dabigatran, the latter group had a significantly higher rate of major bleeding complications (9 patients, 6%), all of which were pericardial tamponade requiring drainage. Major bleeding (pericardial tamponade) was observed in only one patient (1%) in the warfarin group.…”
Section: Article P 2337mentioning
confidence: 95%
“…52 Regarding the periablation use of NOACs, data accumulated over the past few years mostly rely upon small, often retrospective, observational studies on dabigatran (there are no published data on factor Xa inhibitors in patients undergoing AF ablation, as yet), with significant differences in study design, patients' characteristics or procedure-related factors, all of which might have contributed to the contrasting results of those studies. [53][54][55][56][57][58][59][60] In general, late discontinuation of dabigatran (<24 h) before ablation and/or too early reinitiation of dabigatran (within first several hours after the procedure) were associated with increased risk of both thromboembolic and bleeding events compared with uninterrupted warfarin, while an earlier dabigatran discontinuation and later reinitiation (≥4 h after the procedure), with appropriate LMWH bridging, appeared to be as safe and effective as uninterrupted warfarin. However, the most recent study (also retrospective, but the largest published so far) found that uninterrupted administration of dabigatran 150 mg twice daily (including the day of the procedure), was as safe and effective as uninterrupted warfarin.…”
Section: Periprocedural Cessation Of Oral Anticoagulant Therapymentioning
confidence: 97%
“…The evidence network for the primary analysis (figure 2) included 31 studies and six observational studies (52,(55)(56)(57)(58)62)) reporting on 287, 692 patients exposed to 230, 090 years of anticoagulant medication. We were unable to separate out upper and lower GI bleeds as most of the studies did not include this information.…”
Section: Major Gi Bleedingmentioning
confidence: 99%